Comparative Pharmacology
Head-to-head clinical analysis: SULF 10 versus SULFAIR 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULF 10 versus SULFAIR 10.
SULF-10 vs SULFAIR 10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production.
Bacteriostatic inhibitor of dihydropteroate synthase, blocking folic acid synthesis in susceptible bacteria.
One to two drops of SULF-10 ophthalmic solution (10% sulfacetamide sodium) instilled into the affected eye(s) every 2-3 hours initially, then decreasing frequency as infection resolves, up to 5-6 times daily.
5 mg orally once daily, taken at bedtime.
None Documented
None Documented
Terminal elimination half-life is 7-12 hours in adults with normal renal function; prolonged in renal impairment
Terminal elimination half-life of 8-12 hours in adults with normal renal function (CrCl >60 mL/min); extends to 20-30 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal excretion of unchanged drug and acetylated metabolites: ~85-90%; biliary/fecal: ~10-15%
Renal excretion of unchanged drug (approximately 70-80%) and hepatic metabolism (20-30% as metabolites). Fecal elimination is minimal (<5%).
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)